Opioid Analgesics Market Assessment, By Product Type [Codeine, Morphine, Oxycodone, Hydrocodone, Methadone, Meperidine, Fentanyl, Hydromorphone, Oxymorphone, Dextromethorphan, Tramadol, Others], By Application [Chronic Pain, Acute Pain], By Route of Admin

Opioid Analgesics Market Assessment, By Product Type [Codeine, Morphine, Oxycodone, Hydrocodone, Methadone, Meperidine, Fentanyl, Hydromorphone, Oxymorphone, Dextromethorphan, Tramadol, Others], By Application [Chronic Pain, Acute Pain], By Route of Administration [Oral, Injectable, Others], By Distribution Channel [Hospital Pharmacy, Retail Pharmacy, Others], By Region, Opportunities and Forecast, 2017-2031F



Global semen analysis market is projected to witness a CAGR of 5.05% during the forecast period 2024-2031, growing from USD 1,552.23 million in 2023 to USD 2,302.11 million in 2031. The global semen analysis market is expected to keep growing at a robust pace during the forecast period owing to rising awareness about reproductive health, growing cases of infertility, lifestyle habits, and heavy emphasis on diagnosis and treatment of infertility cases from the user end.

Semen analysis, or sperm count analysis, evaluates sperm health by measuring sperm count, motility, and morphology. Products and services in this market include laboratory testing, at-home sperm count kits, and fertility consultations, all aimed at diagnosing male infertility and guiding treatment options. Over the last decade, society has witnessed a huge change in lifestyle and food habits that severely impacted overall human health, including fertility. These changes, coupled with growing awareness about reproductive health, advancements in diagnostics, growing preference for male health, and innovative product launches and services, further enhance the semen analysis market growth. Product launch and market expansion further fuel the market growth; for instance, DYNEVAL LTD. launched its portable semen analyzer, Dynescan, in Bolivia in April 2024, following a successful visit during the DBT Agri-Tech Trade Mission. The partnership with Union Agronegocios SRL aims to enhance the quality assurance of semen during transport and storage. The analyzer features a new fertility marker, SML (Sustained Motility Lifetime), which could improve conception rates by up to 8%.

Growing Cases of Male Infertility Boosts Market Growth

The growing prevalence of male infertility is a significant driving force for the growth of the semen analysis market. Factors such as unhealthy lifestyles, environmental pollutants, and rising stress levels contribute to declining sperm quality globally. Apart from these, exposure to endocrine disruptors and pollutants like pesticides, heavy metals, and industrial chemicals have been linked to reduced fertility. As more couples face challenges with conception, the demand for comprehensive fertility assessments, including semen analysis, continues to rise. The increasing incidents of male infertility are becoming not only a pressing issue but also a growth stimulus in the semen analysis market. Awareness and technological innovation boost demand for accurate yet accessible semen testing. These trends form a dynamic climate both for healthcare providers and manufacturers as they open the scope for innovative investment in the realm of reproductive health. For instance, according to the Human Reproduction Programme (HRP) annual report published in April 2023, globally, 1 in 6 people are estimated to be affected by infertility. In another study published in the “Human Reproduction Update” journal, the global sperm counts fell on average by 1.2% per year between 1973 to 2018, from 104 to 49 million/ml, and year 2000 afterward, this rate of decline accelerated to more than 2.6% per year.

Rising Awareness About Fertility Testing Drives Market Growth

Growing awareness about fertility testing is an essential driving force for the semen analysis market. Societal attitudes regarding the need for greater openness over reproductive health issues are helping raise people's awareness about male fertility playing an important part in general couple infertility, accounting for a significant share of the global prevalence of infertility. Advocacy groups and healthcare organizations are now conducting public awareness campaigns on male infertility to educate people about testing sperm count. Public awareness campaigns, demystifying the whole process and encouraging men to seek tests increase the demand for semen analysis services. Therefore, the semen analysis market growth is primarily dependent upon increasing awareness of fertility testing. Public awareness and education, technical innovations in technology, the changes brought about in lifestyles, access to improved healthcare facilities, and even the comfort of online purchase options inspire men to address their reproductive concerns actively. Along with the continued removal of the social stigma related to such topics and through enhanced awareness, semen analysis services will grow enormously during the next couple of years.

For instance, every year, the last week of April is celebrated as National Infertility Awareness Week to spread awareness about infertility and its management options. Several organizations, like the American Society for Reproductive Medicine and the National Infertility Association, run various campaigns to spread awareness about the same.

Dominance of Fertility Centers Segment in Market

Fertility centers specialize in a broad spectrum of reproductive health services. They are important to the couple suffering from infertility. A proper evaluation, such as a sperm function test, is essential for developing individualized treatment plans. The ability to take a holistic approach from the first testing process to the possible treatments of in-vitro fertilization positions and fertility centers forms an integral part of the sperm analysis market. Having had a significant market share, increased awareness of male infertility, the rapid advancement of modern technology in diagnostic practices, and extensive services within a fertility center cement these leaders within the market on sperm analysis. Because trends may always take an evolving path forward, then fertility centers stand tall and firm in this future trend on addressing the concerns associated with male infertility using appropriate approaches through sperm analysis and related interventions.

In July 2024, Legacy, a leading digital fertility clinic for men, introduced an upgraded at-home sperm testing and freezing kit. This new version features a patented conical collection cup for accurate volume reporting, enhanced insulation for temperature control, and a tamper-proof padlock seal. Designed based on client feedback, the kit aims to improve user experience and security. Legacy continues to prioritize accessibility in fertility preservation, reflecting its commitment to customer service and innovation in male reproductive health.

North America Dominates the Semen Analysis Market

North America is anticipated to be the dominant region in the semen analysis market. This leadership is driven by advanced healthcare infrastructure, high adoption of innovative technologies, and increased awareness of male reproductive health issues. The region benefits from robust research and development activities, leading to the introduction of cutting-edge sperm testing products. Additionally, supportive government policies and favorable reimbursement frameworks boost market growth. The rising prevalence of male infertility and the demand for assisted reproductive technologies further solidifies North America's position as a leader in this sector. Additionally, authorities in the region also contribute to the market expansion through their efforts; for instance, the American Urological Association (AUA), in collaboration with the American Society for Reproductive Medicine (ASRM), has released the 2024 amendment to its Male Infertility Guideline. This updated guideline offers a comprehensive approach to evaluating and managing male infertility, emphasizing thorough patient history, physical exams, and necessary diagnostic testing. Key updates include recommendations on azoospermia evaluation, karyotype testing, imaging modalities, and the use of testicular sperm in non-azoospermic patients. Additionally, it revises WHO reference ranges for semen characteristics and introduces a new table defining common semen analysis terms, aiming to improve male reproductive health and overall well-being.

Future Market Scenario (2024-2031F)

Futuristic advancements in the analysis of sperm, in particular, reform much of the market with the integration of AI and advanced imaging technology. Traditional semen analysis, being manual, allows considerable subjectivity and a plethora of human errors wherein such variability goes into determining results. The alternative given to this is that AI-driven semen analysis gives a structured approach that is devoid of as much human intervention, lending towards a standardized measure for assessing parameters of semen related to sperm count, motility, and even morphology. AI technologies rapidly process images through advanced algorithms such that thousands of sperm images are analyzed with unprecedented precision. Automating these results reduces turn-around times and creates laboratory workflow streams for fast, efficient sperm analysis. Another aspect of AI is predicting the male potential for fertility, taking information from multiple points, whether in medical history or personal life, thereby allowing individually targeted treatment. The advent of automated systems, including computer-aided sperm analysis (CASA), will further support these developments. These systems can provide reliable diagnostics that improve clinical decision-making. The promise of improved male reproductive health outcomes and access to fertility assessments through the continued evolution of these technologies will further transform the landscape of fertility evaluation and treatment.

Key Players Landscape and Outlook

The semen analysis market is segmented into products used for such analysis and services provided to patients for semen analysis. The service market is quite fragmented due to a large number of local and global market players, while medical device manufacturers dominate the product market. Recent market activities include product and service launches, new center setups, and business agreements like mergers and acquisitions.

In July 2024, Hamilton Thorne Inc. agreed to be acquired by Astorg Partners. This acquisition aims to enhance Hamilton Thorne's capabilities in advanced semen analysis technologies, which are crucial for fertility treatments and reproductive health. The deal is expected to provide additional resources and support for the company's innovative products and services, positioning it for future growth in the reproductive health sector. The transaction is subject to customary closing conditions and regulatory approvals.


1. Project Scope and Definitions
2. Research Methodology
3. Executive Summary
4. Global Opioid Analgesics Market Outlook, 2017-2031F
4.1. Market Size Analysis & Forecast
4.1.1. By Value
4.2. Market Share Analysis & Forecast
4.2.1. By Products Type
4.2.1.1. Codeine
4.2.1.2. Morphine
4.2.1.3. Oxycodone
4.2.1.4. Hydrocodone
4.2.1.5. Methadone
4.2.1.6. Meperidine
4.2.1.7. Fentanyl
4.2.1.8. Hydromorphone
4.2.1.9. Oxymorphone
4.2.1.10. Dextromethorphan
4.2.1.11. Tramadol
4.2.1.12. Others
4.2.2. By Application
4.2.2.1. Chronic Pain
4.2.2.2. Acute Pain
4.2.3. By Route of Administration
4.2.3.1. Oral
4.2.3.2. Injectable
4.2.3.3. Others
4.2.4. By Distribution
4.2.4.1. Hospital Pharmacy
4.2.4.2. Retail Pharmacy
4.2.4.3. Others
4.2.5. By Region
4.2.5.1. North America
4.2.5.2. Europe
4.2.5.3. Asia-Pacific
4.2.5.4. South America
4.2.5.5. Middle East and Africa
4.2.6. By Company Market Share Analysis (Top 5 Companies and Others – By Value, 2023)
4.3. Market Map Analysis, 2023
4.3.1. By Product Type
4.3.2. By Application
4.3.3. By Route of Administration
4.3.4. By Distribution
4.3.5. By Region
5. North Opioid Analgesics Market Outlook, 2017-2031F*
5.1. Market Size Analysis & Forecast
5.1.1. By Value
5.2. Market Share Analysis & Forecast
5.2.1. By Products Type
5.2.1.1. Codeine
5.2.1.2. Morphine
5.2.1.3. Oxycodone
5.2.1.4. Hydrocodone
5.2.1.5. Methadone
5.2.1.6. Meperidine
5.2.1.7. Fentanyl
5.2.1.8. Hydromorphone
5.2.1.9. Oxymorphone
5.2.1.10. Dextromethorphan
5.2.1.11. Tramadol
5.2.1.12. Others
5.2.2. By Application
5.2.2.1. Chronic Pain
5.2.2.2. Acute Pain
5.2.3. By Route of Administration
5.2.3.1. Oral
5.2.3.2. Injectable
5.2.3.3. Others
5.2.4. By Distribution
5.2.4.1. Hospital Pharmacy
5.2.4.2. Retail Pharmacy
5.2.4.3. Others
5.2.5. By Country Share
5.2.5.1. United States
5.2.5.2. Canada
5.2.5.3. Mexico
5.3. Country Market Assessment
5.3.1. United States Opioids Analgesics Market Outlook, 2017-2031F*
5.3.1.1. Market Size Analysis & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share Analysis & Forecast
5.3.1.2.1. By Product type
5.3.1.2.1.1. Codeine
5.3.1.2.1.2. Morphine
5.3.1.2.1.3. Oxycodone
5.3.1.2.1.4. Hydrocodone
5.3.1.2.1.5. Methadone
5.3.1.2.1.6. Meperidine
5.3.1.2.1.7. Fentanyl
5.3.1.2.1.8. Hydromorphone
5.3.1.2.1.9. Oxymorphone
5.3.1.2.1.10. Dextromethorphan
5.3.1.2.1.11. Tramadol
5.3.1.2.1.12. Others
5.3.1.2.2. By Application
5.3.1.2.2.1. Chronic Pain
5.3.1.2.2.2. Acute Pain
5.3.1.2.3. By Route of Administration
5.3.1.2.3.1. Oral
5.3.1.2.3.2. Injectable
5.3.1.2.3.3. Others
5.3.1.2.4. By Distribution
5.3.1.2.4.1. Hospitals Pharmacy
5.3.1.2.4.2. Retail Pharmacy
5.3.1.2.4.3. Others
5.3.2. Canada
5.3.3. Mexico
*All segments will be provided for all regions and countries covered
6. Europe Opioid Analgesics Market Outlook, 2017-2031F
6.1. Germany
6.2. France
6.3. Italy
6.4. United Kingdom
6.5. Russia
6.6. Netherlands
6.7. Spain
6.8. Poland
7. Asia-Pacific Opioids Analgesics Market Outlook, 2017-2031F
7.1. India
7.2. China
7.3. Japan
7.4. Australia
7.5. Vietnam
7.6. South Korea
7.7. Indonesia
7.8. Philippines
8. South America Opioid Analgesics Market Outlook, 2017-2031F
8.1. Brazil
8.2. Argentina
9. Middle East and Africa Opioid Analgesics Market Outlook, 2017-2031F
9.1. Saudi Arabia
9.2. UAE
9.3. South Africa
9.4. Israel
10. Demand Supply Analysis
11. Import and Export Analysis
12. Value Chain Analysis
13. Porter’s Five Forces Analysis
14. PESTLE Analysis
15. Pricing Analysis
16. Market Dynamics
16.1. Market Drivers
16.2. Market Challenges
17. Market Trends and Developments
18. Regulatory Framework and Innovation
18.1. Clinical Trials
18.2. Regulatory Approvals
19. Patent Landscape
20. Case Studies
21. Competitive Landscape
21.1. Competition Matrix of Top 5 Market Leaders
21.2. SWOT Analysis for Top 5 Players
21.3. Key Players Landscape for Top 10 Market Players
21.3.1. Pfizer Inc.
21.3.1.1. Company Details
21.3.1.2. Key Management Personnel
21.3.1.3. Products and Services
21.3.1.4. Financials (As Reported)
21.3.1.5. Key Market Focus and Geographical Presence
21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
21.3.2. Johnson & Johnson Services, Inc.
21.3.3. Teva Pharmaceuticals Industries Ltd.
21.3.4. Endo Pharmaceuticals Inc.
21.3.5. Sun Pharmaceuticals Industries Ltd.
21.3.6. Bayer AG
21.3.7. Abbott Laboratories
21.3.8. Purdue Pharma L.P.
21.3.9. Hikma Pharmaceuticals PLC.
21.3.10. Sanofi S.A.
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
22. Strategic Recommendations
23. About Us and Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings